PEAK1 and colorectal carcinoma: Another study (Ding et al., 2019) have also reported that the pseudopodium-enriched atypical kinase 1-PPP1R12B axis inhibits colorectal tumourigenesis and metastasis through the deactivation of the Grb2/PI3K/Akt pathway, which might provide a novel therapeutic strategy for CRC treatment.